
Major Scope
- Colon and Rectal Surgery
- General Surgery
- Gynecologic Oncology
- Plastic Surgery
- Neurological Surgery
- Orthopaedic Surgery
- Orthopaedic Surgery of the Spine
- Neonatal Surgery
- Prenatal Surgery
- Trauma Surgery
- Surgical Intensivists, Specializing In Critical Care Patients
- Thoracic Surgery
- Congenital Cardiac Surgery
- Thoracic Surgery-Integrated
- Vascular Surgery
Abstract
Citation: Clin Surg. 2024;9(1):3719.Research Article | Open Access
Antiemetic Activity of Fosaprepitant as a Rescue Agent in Patients with Postoperative Nausea and Vomiting after Orthopedic Surgery
Saleh JN
Department of Pharmacy, The Hospital for Special Surgery, USA
*Correspondance to: Jawad N Saleh
PDF Full Text DOI: 10.25107/2474-1647.3719
Abstract
Background: Postoperative Nausea and Vomiting (PONV) is a common postoperative complication in the orthopedic surgical setting which may result in significant consequences. Many agents exist for PONV prophylaxis but rescue options remain a big challenge. Fosaprepitant has been studied in PONV prophylaxis but ‘evidence for use of Neurokinin-1 Receptor Antagonists (NK-1 RA) for PONV rescue is lacking. Assessing fosaprepitant as a rescue agent for PONV in the orthopedic surgical population was warranted. Methods: In this single center retrospective chart review, the antiemetic activity of fosaprepitant (selective NK1 receptor antagonist) was investigated as a rescue agent for PONV in patients undergoing orthopedic surgery. Based on the institutional protocol, fosaprepitant was only utilized in patients who experienced PONV with an existing history of PONV or when 2 antiemetic agents were exhausted with no success in the postoperative period. Chart reviews, progress notes, electronic message requests, pyxis medication removal reports and clinical interventions were utilized to assess emesis relief. The primary outcome was to assess fosaprepitant’s effect as a rescue agent for PONV in the orthopedic surgical setting. Results: A total of 383 patients (over a 12-month period) were approved based on the hospital protocol to receive fosaprepitant as a rescue agent. Out of the 383 patients, 286 had relief with fosaprepitant, with 196 patients not requiring further antiemetic therapy. Patient demographics, anesthesia type, additional medications and surgical types were all assessed thoroughly. Three of the surgical types showed the potential significance for fosaprepitant PONV relief: Sports management and shoulder 81% (p=0.0012), adult reconstruction and joint replacement 78% (<0.0001), Spine 66% (p=0.015). Conclusion: The data shows there may be potential for utilizing fosaprepitant as a rescue agent for PONV in the orthopedic setting. A bigger study with a larger sample size is encouraged.
Keywords
Vomiting; Nausea; PONV; Antiemetics; Pharmacology; Fosaprepitant; Surgery; Orthopedics
Cite the article
Saleh JN. Antiemetic Activity of Fosaprepitant as a Rescue Agent in Patients with Postoperative Nausea and Vomiting after Orthopedic Surgery. Clin Surg. 2024; 9: 3719..
Journal Basic Info
- Impact Factor: 2.395**
- H-Index: 8
- ISSN: 2474-1647
- DOI: 10.25107/2474-1647
- NLM ID: 101702548